Green Thumb Industries Inc. (CNSX: GTII)
Health Care · Pharmaceuticals · US
CA$9.51
+1.06% today · -24.7% 1Y
Green Thumb Industries Inc. (CNSX: GTII) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.46B and employs 4,900 people.
Over the last twelve months the share price has lost 24.7%, trading between 7.40 and 14.39.
Tweenvest scores Green Thumb Industries Inc. across four factors: quality 67/100, value 71/100, growth 73/100. Its strongest factor is growth.
GTII price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.46B
- Revenue (TTM)
- $1.21B
- P/E
- 12.09
- EPS
- 0.55
- Dividend yield
- —
- Beta (5Y)
- 0.95
- 52-week high
- CA$14.39
- 52-week low
- CA$7.40
- Avg volume (3M)
- —
- Shares outstanding
- 218.61M
- Employees
- 4,900
- Next earnings
- —
About Green Thumb Industries Inc.
Green Thumb Industries Inc. is a U.S.-based company focused on the cultivation, processing, and distribution of cannabis products for both medicinal and adult recreational consumption. Its diverse product portfolio includes raw cannabis flower and a wide array of manufactured and pre-packaged offerings such as pre-rolls, concentrates, vaporizers, tinctures, edibles, and topicals. These are marketed under well-known brand names including Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, and RHYTHM. The company employs a dual distribution strategy, supplying its products primarily to third-party retail outlets while also engaging in direct-to-consumer sales through its owned and operated dispensaries. As of April 11, 2022, GTI operated a network of 77 retail stores across the United States. Established in 2014, the firm maintains its corporate headquarters in Chicago, Illinois.
- ISIN
- CA39342L1085
- Founded
- 2014
- Listed since
- Oct 28, 2003
- Exchange
- Canadian National Stock Exchange
- Currency
- CAD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Concord Biotech LimitedNSEI: CONCORDBIO | $1.49B | Rs1,374.10 | -5.47% |
| Lotus Pharmaceutical Co., Ltd.TWSE: 1795 | $1.49B | NT$176.00 | +0.28% |
| Nektar TherapeuticsNasdaqCM: NKTR | $1.49B | $40.80 | -6.38% |
| Maze Therapeutics, Inc.NasdaqGM: MAZE | $1.47B | $25.88 | -2.08% |
| Yifan Pharmaceutical Co., Ltd.SZSE: 002019 | $1.46B | CN¥9.42 | +0.64% |
| Tianjin Chase Sun Pharmaceutical Co.,LtdSZSE: 300026 | $1.46B | CN¥3.25 | +2.20% |
| Xiamen Kingdomway Group CompanySZSE: 002626 | $1.45B | CN¥16.13 | -0.37% |
| Ningbo Menovo Pharmaceutical Co., Ltd.SHSE: 603538 | $1.45B | CN¥28.59 | +6.84% |
Figures last refreshed Oct 4, 2026.